Boston Scientific Corporation (NYSE:BSX) will release earnings for its first quarter before the opening bell on Wednesday, April 22.

Analysts expect the Marlborough, Massachusetts-based company to report quarterly earnings of 79 cents per share. That’s up from 75 cents per share in the year-ago period. The consensus estimate for Boston Scientific's quarterly revenue is $5.17 billion (it reported $4.66 billion last year), according to Benzinga Pro.

On March 28, Boston Scientific announced data from its HI-PEITHO clinical trial evaluating the EKOS Endovascular System in patients with pulmonary embolism.

Shares of Boston Scientific fell 2.4% to close at $59.52 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Stifel analyst Rick Wise maintained a Buy rating and cut the price target from $90 to $85 on April 21, 2026. This analyst has an accuracy rate of 69%.
  • Truist Securities analyst Richard Newitter maintained the stock with a Buy rating and lowered the price target from $92 to $90 on April 15, 2026. This analyst has an accuracy rate of 65%.
  • Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and slashed the price target from $115 to $90 on April 13, 2026. This analyst has an accuracy rate of 64%.
  • Citigroup analyst Joanne Wuensch maintained the stock with a Buy rating and cut the price target from $94 to $87 on April 7, 2026. This analyst has an accuracy rate of 69%.
  • Evercore ISI Group analyst Vijay Kumar maintained the stock with an Outperform rating and cut the price target from $96 to $80 on April 6, 2026. This analyst has an accuracy rate of 54%

Considering buying BSX stock? Here’s what analysts think:

Photo via Shutterstock